Alpine Immune Sciences IncNASDAQ:ALPN
- LAST PRICE7.1200
- TODAY'S CHANGE (%)0.1200 (1.7143%)
- Bid / Lots7.0900/ 2
- Ask / Lots7.1500/ 2
- Open / Previous Close6.9700 / 7.0000
- Day Range
- 52 Week Range
- Volume23,882
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALPN |
|---|---|---|
| 09:32 ET | 584 | 7.005 |
| 09:38 ET | 2219 | 7 |
| 09:50 ET | 800 | 6.97 |
| 09:56 ET | 100 | 6.975 |
| 09:57 ET | 700 | 6.98 |
| 10:01 ET | 3800 | 6.995 |
| 10:19 ET | 100 | 7.005 |
| 10:30 ET | 100 | 6.985 |
| 10:53 ET | 375 | 7.0083 |
| 10:57 ET | 294 | 7 |
| 11:02 ET | 100 | 7 |
| 11:06 ET | 200 | 7 |
| 11:09 ET | 200 | 6.99 |
| 11:11 ET | 3500 | 7.025 |
| 11:18 ET | 500 | 7.06 |
| 11:20 ET | 200 | 7.09 |
| 11:49 ET | 500 | 7.15 |
| 11:58 ET | 200 | 7.125 |
| 12:20 ET | 101 | 7.12 |
| 12:21 ET | 100 | 7.11 |
| 12:30 ET | 100 | 7.1 |
| 12:32 ET | 200 | 7.09 |
| 12:41 ET | 100 | 7.09 |
| 12:45 ET | 331 | 7.11 |
| 12:52 ET | 100 | 7.12 |
| 01:10 ET | 100 | 7.12 |
| 01:14 ET | 100 | 7.12 |
| 01:30 ET | 100 | 7.12 |
| 01:32 ET | 100 | 7.12 |
Mar 24, 2023
Alpine Immune Sciences' Q4 Net Loss Narrows, Revenue Falls; Expects Cash Position to Fund Operations Through 2025, from 8:46AM ET on Friday Mar 24, 2023 by MT Newswires
8:46AM ET on Friday Mar 24, 2023 by MT Newswires
Mar 23, 2023
BRIEF-Alpine Immune Sciences Reports Fourth Quarter Results, from 4:16PM ET on Thursday Mar 23, 2023 by Thomson Reuters
4:16PM ET on Thursday Mar 23, 2023 by Thomson Reuters-- Earnings Flash (ALPN) ALPINE IMMUNE SCIENCES Posts Q4 Revenue $2.8M, vs. Street Est of $11M, from 4:07PM ET on Thursday Mar 23, 2023 by MT Newswires
4:07PM ET on Thursday Mar 23, 2023 by MT NewswiresAlpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results, from 4:05PM ET on Thursday Mar 23, 2023 by Business Wire
4:05PM ET on Thursday Mar 23, 2023 by Business Wire
Mar 22, 2023
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Alpine Immune Sciences Inc | 334.3M | -4.1x | --- |
AVITA Medical Inc | 338.7M | -12.7x | --- |
Tarsus Pharmaceuticals Inc | 325.3M | -4.8x | --- |
Tango Therapeutics Inc | 333.3M | -3.3x | --- |
Voyager Therapeutics Inc | 314.3M | -5.9x | --- |
OmniAb Inc | 388.0M | -12.0x | --- |
Company Information
Alpine Immune Sciences, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The Company's scientific platform uses a directed evolution process to convert native immune system proteins from the immunoglobulin super family (IgSF) into multi-targeted therapeutics capable of modulating the human immune system. Its product candidates include ALPN-101, ALPN-202 and ALPN-303. ALPN-101 is a dual inducible T cell costimulator (ICOS) and cluster of differentiation 28 (CD28) antagonist intended for the treatment of autoimmune and inflammatory diseases. Its oncology program is ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer. ALPN-303 is a dual B-cell cytokine antagonist for the treatment of B-cell mediated diseases.
Contact Information
- Headquarters
- 188 East Blaine St., Suite 200SEATTLE, WA, United States 98102
- Phone
- 206-788-4545
- Fax
- 302-636-5454
Executives
- Executive Chairman of the Board, Chief Executive Officer
- Mitchell Gold
- President, Head - Research and Development
- Stanford Peng
- Chief Financial Officer, Senior Vice President, Corporate Secretary
- Paul Rickey
- Chief Medical Officer
- Andrew Sandler
- Director
- Jorn Drappa
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $334.3M |
|---|---|
Revenue (TTM) | $30.1M |
Shares Outstanding | 47.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.28 |
EPS | $-1.75 |
Book Value | $3.90 |
P/E Ratio | -4.1x |
Price/Sales (TTM) | 11.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -193.41% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
